Intended for healthcare professionals

News

Psilocybin reduces symptoms in treatment resistant depression, trial results show

BMJ 2022; 379 doi: https://doi.org/10.1136/bmj.o2623 (Published 02 November 2022) Cite this as: BMJ 2022;379:o2623
  1. Gareth Iacobucci
  1. The BMJ

A single 25 mg dose of psilocybin, the active ingredient in magic mushrooms, has a significant effect on reducing symptoms of depression in people who have so far not benefited from treatment, trial results have shown.1

Researchers investigated the effects of single doses of 25 mg, 10 mg, or 1 mg (control) psilocybin over 12 weeks in 233 patients with treatment resistant depression. They were given the treatment in specialised rooms designed to provide a non-clinical and calming atmosphere where a specially trained therapist was available to provide psychological support. The psychedelic effects of psilocybin last as long as eight hours, and once these had passed the participants were able to return home. …

View Full Text

Log in

Log in through your institution

Subscribe

* For online subscription